Ameliorating bronchiolitis oblietrans after transplantation using hemoglobin vesicles by controlling ADAM/MMP expressions.

Research Project

Project/Area Number	26462134
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Multi-year Fund
Section	一般
Research Field	Respiratory surgery
Research Institution	Keio University
Principal Investigator	Ohtsuka Takashi 慶應義塾大学, 医学部(信濃町), 准教授 (40306717)
Co-Investigator(Kenkyū-buntansha)	下田将之慶應義塾大学, 医学部(信濃町), 講師 (70383734) 安樂真樹東京大学, 医学部附属病院, 特任准教授 (70598557)
Project Period (FY)	2014-04-01 – 2017-03-31
Project Status	Completed (Fiscal Year 2016)
Budget Amount *help	¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000) Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000) Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000) Fiscal Year 2014: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Keywords	肺移植 / 拒絶反応 / メタロプロテアーゼ / マトリックスメタロプロテアーゼ / 肺移植拒絶反応
Outline of Final Research Achievements	Acute rejection after lung transplantation is the main risk factor for the development of bronchiolitis obliterans (BO). We investigated inhibitor of Matrix metalloproteinases (MMPs) could ameliorate acute rejection in mouse trachea transplantation model. MMP inhibitor was given to the transplanted mice. The acute rejection of tracheal transplant was decreased in the allograft treated with MMP inhibitor. Regulatory T-cell infiltration and IL-10 mRNA expression increased in the allograft treated with MMP inhibitor. MMP inhibitor could be the treatment option for BO after lung transplantation.